Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in ProCellEx庐 plant cell-based protein expression system, will release its Q2 2025 financial results on August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. EDT to discuss financial results and provide corporate and regulatory updates.
The conference call will be accessible via multiple channels, including toll-free numbers for US and Israeli participants, and will feature a convenient Call me鈩� feature. A webcast replay will be available for two weeks following the presentation on the company's investor relations website.
Protalix BioTherapeutics (NYSE American: PLX), un'azienda biofarmaceutica specializzata nel sistema di espressione proteica basato su cellule vegetali ProCellEx庐, pubblicher脿 i suoi risultati finanziari del secondo trimestre 2025 il 14 agosto 2025. L'azienda terr脿 una conference call e una trasmissione in webcast alle 8:30 a.m. EDT per discutere i risultati finanziari e fornire aggiornamenti aziendali e normativi.
La conference call sar脿 accessibile tramite diversi canali, inclusi numeri verdi per i partecipanti statunitensi e israeliani, e includer脿 una comoda funzione Call me鈩�. Una replica del webcast sar脿 disponibile per due settimane dopo la presentazione sul sito web delle relazioni con gli investitori della societ脿.
Protalix BioTherapeutics (NYSE American: PLX), una compa帽铆a biofarmac茅utica especializada en el sistema de expresi贸n de prote铆nas basado en c茅lulas vegetales ProCellEx庐, publicar谩 sus resultados financieros del segundo trimestre de 2025 el 14 de agosto de 2025. La empresa realizar谩 una conferencia telef贸nica y una transmisi贸n por webcast a las 8:30 a.m. EDT para analizar los resultados financieros y ofrecer actualizaciones corporativas y regulatorias.
La conferencia telef贸nica ser谩 accesible a trav茅s de m煤ltiples canales, incluyendo n煤meros gratuitos para participantes de EE.UU. e Israel, y contar谩 con una pr谩ctica funci贸n Call me鈩�. Una repetici贸n del webcast estar谩 disponible durante dos semanas despu茅s de la presentaci贸n en el sitio web de relaciones con inversores de la compa帽铆a.
Protalix BioTherapeutics (NYSE American: PLX)電� ProCellEx庐 鞁濍 靹疙彫 旮半皹 雼氨歆� 氚滍槃 鞁滌姢韰滌潉 鞝勲鞙茧 頃橂姅 靸濍獏瓿淀暀 須岇偓搿滌劀, 2025雲� 8鞗� 14鞚检棎 2025雲� 2攵勱赴 鞛 瓴瓣臣毳� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 須岇偓電� 鞛 瓴瓣臣毳� 雲检潣頃橁碃 旮办梾 氚� 攴滌牅 鞐呺嵃鞚错姼毳� 鞝滉车頃橁赴 鞙勴暣 霃欕秬 響滌鞁� 鞓れ爠 8鞁� 30攵�鞐� 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 臧滌禍頃╇媹雼�.
旎嵓霟办姢 旖滌潃 氙戈淡瓿� 鞚挫姢霛检棙 彀戈皜鞛愲ゼ 鞙勴暅 氍措 鞝勴檾氩堩樃毳� 韽暔頃� 鞐煬 毂勲剱鞚� 韱淀暣 鞝戩啀頃� 靾� 鞛堨溂氅�, 韼鸽Μ頃� Call me鈩� 旮半姤霃� 鞝滉车霅╇媹雼�. 鞗轨簮鞀ろ姼 鞛癌靻§潃 氚滍憸 頉� 2欤缄皠 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 鞚挫毄 臧�電ロ暕雼堧嫟.
Protalix BioTherapeutics (NYSE American : PLX), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans le syst猫me d'expression prot茅ique 脿 base de cellules v茅g茅tales ProCellEx庐, publiera ses r茅sultats financiers du deuxi猫me trimestre 2025 le 14 ao没t 2025. La soci茅t茅 tiendra une conf茅rence t茅l茅phonique et une diffusion en webcast 脿 8h30 EDT pour discuter des r茅sultats financiers et fournir des mises 脿 jour corporatives et r茅glementaires.
La conf茅rence t茅l茅phonique sera accessible via plusieurs canaux, incluant des num茅ros verts pour les participants am茅ricains et isra茅liens, et proposera une fonction Call me鈩� pratique. Une rediffusion du webcast sera disponible pendant deux semaines apr猫s la pr茅sentation sur le site des relations investisseurs de la soci茅t茅.
Protalix BioTherapeutics (NYSE American: PLX), ein biopharmazeutisches Unternehmen, das sich auf das ProCellEx庐-Pflanzenzell-basiertes Proteinausdruckssystem spezialisiert hat, wird seine Finanzergebnisse f眉r das zweite Quartal 2025 am 14. August 2025 ver枚ffentlichen. Das Unternehmen veranstaltet um 8:30 Uhr EDT eine Telefonkonferenz und einen Webcast, um die Finanzergebnisse zu besprechen und Unternehmens- sowie regulatorische Updates zu geben.
Die Telefonkonferenz ist 眉ber mehrere Kan盲le zug盲nglich, darunter geb眉hrenfreie Nummern f眉r Teilnehmer aus den USA und Israel, und bietet eine praktische Call me鈩�-Funktion. Eine Wiederholung des Webcasts wird f眉r zwei Wochen nach der Pr盲sentation auf der Investor-Relations-Website des Unternehmens verf眉gbar sein.
- None.
- None.
Company to host conference call and webcast at 8:30 a.m. EDT
CARMIEL,
Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.
Conference Call Details: | |
Date:听 | Thursday, August听14, 2025 |
Time:听 | 8:30 a.m. Eastern Daylight Time听(EDT) |
Toll Free:听 | 1-877-423-9813 |
International:听 | 1-201-689-8573 |
Israeli Toll Free:听 | 1-809-406-247 |
Conference ID:听 | 13755073 |
Call me鈩�:听听 听 |
|
The Call me鈩� feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away. | |
Webcast Details:听 | |
The conference will be webcast live from the Protalix website and will be available via the following links: | |
Company Link: 听 |
|
Webcast Link:听 |
|
Conference ID: 听 | 13755073 |
Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S.听Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX鈥�115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX鈥�119, a plant cell-expressed long acting DNase听I for the treatment of NETs-related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306听
[email protected]
Logo -听https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When will Protalix BioTherapeutics (PLX) release Q2 2025 earnings?
How can investors access Protalix BioTherapeutics' Q2 2025 earnings call?
Will there be a replay available of Protalix BioTherapeutics' Q2 2025 earnings call?
What does Protalix BioTherapeutics' ProCellEx technology do?
